



ASX Announcement

Clarification of Announcement - Medlab UNSW Sydney Laboratory Collaboration

SYDNEY, August 02, 2022 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), an Australian biotech using delivery technology to enhance medicines effectiveness wishes to provide further details to the UNSW Sydney Laboratory collaboration.

- The term of the agreement is for one year, renewable (subject to UNSW and Medlab approval)
- Consideration for the Lab space and ancillaries' costs is \$90K per annum, as compared to \$240K + per annum in current physical lease at Alexandria, Sydney
- Other OPEX savings included in lab running costs, gas, electricity, water, insurance, and security
- This contract comes to effective immediately with no other conditions precedent required

For and behalf of the Board.

Dr Sean Hall
Managing Director

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery technology, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain.

NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory.

NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

For further information contact:

Dr. Sean Hall, CEO

Medlab Clinical Ltd

T: +61 411 603 378 E: sean_hall@medlab.co